论文部分内容阅读
应用单克隆抗体Ｃ－ｅｒｂＢ－２肿瘤蛋白及免疫组化（ＬＳＡＢ）法，对８４例乳腺浸润性导管癌作Ｃ－ｅｒｂＢ－２癌基因蛋白产物表达（简称Ｃ－ｅｒｂＢ－２表达）检测并与随诊资料进行比较分析，结果（１）Ｃ－ｅｒｂＢ－２在本组病例的表达率为５５．９％（４７／８４）。（２）Ｃ－ｅｒｂＢ－２表达与肿瘤的ＴＮＭ分期、复发／远必转移、５ａ生存率无相关性（Ｐ＞０．０５）、而仅与腋淋巴结转移状况和２ａ死亡率有关（Ｐ＜０．００５及Ｐ＜０．０５）。（３）有／无淋巴结转移病例的Ｃ－ｅｒｂＢ－２表达与患者的预后均无关（Ｐ＞０．７５）。结果提示Ｃ－ｅｒｂＢ－２表达不宜作为乳腺浸润性导管癌的预后指标。
Using monoclonal antibody C-erbB-2 tumor protein and immunohistochemistry (LSAB) method, the expression of C-erbB-2 oncogene protein product (abbreviated as C-erbB-2) was detected in 84 cases of breast invasive ductal carcinoma. Compared with follow-up data, the results (1) the expression rate of C-erbB-2 in this group of patients was 55.9% (47/84). (2) There was no correlation between C-erbB-2 expression and tumor TNM stage, recurrence/reasonable metastasis, 5-year survival rate (P>0.05), but only with axillary lymph node metastasis and 2a mortality (P< 0.005 and P<0.05). (3) The expression of C-erbB-2 in patients with/without lymph node metastasis was not related to the prognosis of patients (P>0.75). The results suggest that C-erbB-2 expression should not be used as a prognostic indicator of breast invasive ductal carcinoma.